))
Episode 41: David Esposito - President and CEO at ONL Therapeutics
Manage episode 382347667 series 3526490
Contenuto fornito da Vial. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Vial o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
What if your vision could be saved by the precise application of innovative biotech? Join us as we talk to David Esposito, President & CEO of ONL Therapeutics, and delve deep into his take on leadership. He shares how his military background has been instrumental in the successful management of clinical trials, particularly when navigating the unpredictable terrain of the COVID-19 pandemic. With their pipeline ONL1204, a FAS inhibitor targeting retinal disease, O&L Therapeutics is making significant strides in the ophthalmology space.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Capitoli
1. Episode 41: David Esposito - President and CEO at ONL Therapeutics (00:00:00)
2. Managing Clinical Trials (00:00:06)
3. Precision Medicine in Ophthalmology (00:13:07)
62 episodi
Condividi
